Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Halia Therapeutics to Present at the 2023 BIO CEO & Investor Conference


SALT LAKE CITY, Jan. 30, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that David J. Bearss, Ph.D., CEO of Halia Therapeutics, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7.

Dr. Bearss' presentation will highlight the recent company developments on its novel therapeutics to treat chronic inflammatory and neurodegenerative diseases, ongoing pipeline progress, clinical trial updates and anticipated milestones. Details about the presentation are as follows:

Presenter: David J. Bearss, Ph.D., CEO of Halia Therapeutics
Date: Tuesday, February 7, 2023, at 10:45 a.m. EST
Location: Winter Garden Room, Marriott Marquis, New York, NY
Registration: Here

In its 25th year, BIO CEO is one of the largest investor conferences in the life science industry. Halia will be available for in person and virtual partnering meetings. Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering.

About Halia Therapeutics, Inc.

Halia Therapeutics is discovering and developing a pipeline of novel therapeutics to improve the lives of patients with chronic inflammatory disorders and neurodegenerative diseases, with its initial programs targeting NEK7 and LRRK2. Halia's lead candidate, HT-6184, a novel NEK7/NLRP3 inhibitor, is currently completing a Phase 1 study (NCT05447546) evaluating the safety and tolerability of HT-6184 when administered as single or multiple oral doses at escalating dose levels in healthy volunteer subjects. The company is headquartered in Salt Lake City, Utah. For more info, visit www.haliatherapeutics.com or follow us on LinkedIn.

Company Contact:
Jeff Burton
[email protected]
+1.385.355.4315

Media Contact:
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
+1 (646) 942-5604
[email protected]

SOURCE Halia Therapeutics


These press releases may also interest you

at 07:05
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
MindMed to Present at Upcoming May Medical Conferences
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Firms in France Seek to Squeeze More Value From Salesforce
Enterprises in France, seeking better returns on investment, are turning to service providers that can manage their Salesforce platforms more efficiently, according to a new research report published today by Information Services Group (ISG) , a...

at 07:05
Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...

More news about Science and technology...


News published on and distributed by: